logo-loader
viewEnquest Plc

EnQuest strikes decommissioning deal with BP for North Sea fields

“The transaction aligns the interests of the parties involved in the production and decommissioning phases, reflecting the industrial logic for the operator to undertake the decommissioning of these assets"

oil and gas operations
EnQuest will receive US$30mln in cash

EnQuest Plc (LON:ENQ) has reached agreement with BP Plc (LON:BP) in regards to the decommissioning of Thistle and Deveron fields in the North Sea.

The smaller oil firm will receive US$30mln in cash from BP and, in exchange, it will manage the physical decommissioning. EnQuest will also be responsible for certain future decommissioning costs, 3.7% of the gross costs capped at a maximum of £57mln.

Cash options

EnQuest will also have the option to receive a further US$20mln in cash, and in return it would assume responsibility for additional future decommissioning payments (a further 2.4% of gross costs, up to a cap of £42mln).

“The transaction aligns the interests of the parties involved in the production and decommissioning phases, reflecting the industrial logic for the operator to undertake the decommissioning of these assets," EnQuest said in a statement.

Quick facts: Enquest Plc

Price: 18.69 GBX

AIM:ENQ
Market: AIM
Market Cap: £316.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

8 hours, 27 minutes ago

RNS

Director/PDMR Shareholding

13 hours, 16 minutes ago

Block listing Interim Review

5 days, 11 hours ago

Total Voting Rights

6 days, 9 hours ago

Director/PDMR Shareholding

1 week, 5 days ago

Operations update

2 weeks, 4 days ago

2 min read